Zecs to your false claims posting continually on this stock from the beginning:
1. Phase 2 study already being developed for later this year as per CEO comments today
2. Will have 7 million in total post tax rebates come before phase 2 starts plus non dilutive funding opportunities from Us defence force as stated by CEO
3. partial response- 82 percent protection in heart muscle tissue is not a partial response and 88 percent reduction in cardiac arrest isn’t either.
4. A downstream antagonist blocks the effect of glutamate receptors and intern a glutamate antagonist. This stops the influx of calcium into neurons which is the same for NYR. NA-1 already proved up this concept 2 years ago in human trials. That’s why AGN results will provide a significant response in humans and NYR will do the same because it’s doing the same thing but also protects the heart muscle and risk of sudden cardiac arrest in heart attacks
Enjoy the day and don’t be upset everytime you see the stock rise because it’s 25 million cap valuation is severely undervalued
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)